About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of One-stop Strategy of EVAR and PCI | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNANCT03540342

Evaluation of One-stop Strategy of EVAR and PCI

The study is designed to evaluate the safety and effectiveness of the "one-stop" endovascular intervention strategy for patients with concomitant coronary artery disease and aortic atherosclerotic dis...

Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Min Yang, MD

CONTACT

+861088396173 [email protected]

Kuo Zhang, MD

CONTACT

+8618813019602 [email protected]

Sponsors

Lead Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

It is a registration study, at least 50 patients will be consecutively enrolled and then be allocated into one-stop strategy group or staging strategy group with at least 30 subjects receiving one-stop strategy. In one stop strategy group, percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR). In staging strategy group, PCI will be performed several days after EVAR. The safety and effectiveness will be assessed between the two groups untill 1 year after the operation. The economic index will be evaluated.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Aged from 18 years to 75years, male or female;
•Aortic atherosclerotic disease with the indication of EVAR;
•Coronary heart disease with the indication of PCI;
•Provided informed consent.

Exclusion Criteria

•Acute aortic dissection
•Acute coronary syndrome
•Dysfunction of coagulation system
•Patients with gastrointestinal hemorrhage
•Known allergy to contrasts or antiplatelet drugs
•Renal dysfunction (GFR≤60ml/min)
•Patient with multi-branch coronary preferred CABG

Related studies

Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque

NCT07660419 · Coronary Artery Disease (CAD), Coronary Stenosis

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630 · Coronary Artery Disease

Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry

NCT07565805 · Coronary Artery Disease (CAD)

RECRUITINGPhase 2

Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

NCT07560436 · Heart Failure With Preserved Ejection Fraction (HFPEF), Coronary Artery Disease

Strategic Comparison Of Ischemia-based Versus Plaque Burden and vulnErability-based Revascularization in High-Risk Coronary Artery Disease Patients

NCT07324720 · Coronary Artery Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 30, 2018Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment50

Start dateJun 2018

Last updatedMay 30, 2018

Condition

Coronary Artery Disease Aortic Atherosclerotic Disease

Locations shown

Chinese Academy of Medical Sciences, Fuwai Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions